The activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against bite wound isolates were determined by the agar dilution method. DU-6859a was the most active compound (MICs, <0.125 g/ml) against all Pasteurella species, Staphylococcus aureus, and streptococci; anaerobes were susceptible to <0.5 g/ml, except fusobacteria, which were susceptible to <2 g/ml. Against aerobes, levofloxacin was more active than ofloxacin (MIC at which 90% of isolates are inhibited [MIC 90 ], <1.0 g/ml for both) and sparfloxacin and ciprofloxacin were also active (MIC 90 s, <0.25 and <1 g/ml, respectively).
Bite wound infections are common and grow a wide variety of fastidious bacteria, including anaerobic veterinary species (1, 2) . Many laboratories are unable to isolate this plethora of organisms, since the organisms are phenotypically similar to each other, may be slow growing, and may be missed unless the plates are incubated for an extended period. Recent advances in molecular biological methods have allowed the recognition of new species with different ecological niches and varied host prevalence (6) . In vitro susceptibility studies of these unusual isolates are often not performed due to technical factors or cost constraints. Consequently, the clinician must often rely on published studies to guide both empirical and subsequent specific antimicrobial therapeutic choices.
DU-6859a is a new (Ϫ)-7-[(7S)-amino-5-azaspiro(2,4)heptan-5-yl]-8-chloro-6-fluoro-1[(1R,2S)-cis-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxoquinolone-3-carboxylic acid (5) that has improved in vitro activity against aerobic and anaerobic bacteria (7, 8, 15) . Other new fluoroquinolones with similarly enhanced activity that may offer a therapeutic alternative have recently become available or are under development (4, 13) . To determine the activities of several new fluoroquinolones against a large variety of these pathogenic species, we compared the susceptibilities of 387 recent clinical bite wound isolates.
The strains were previously isolated from bite wounds and identified by standard criteria (6, 10, 14) . The specific sources were dog bites (n ϭ 154), cat bites (n ϭ 153), human bites (n ϭ 53), squirrel bites (n ϭ 2), pig bites (n ϭ 1), monkey bites (n ϭ 2), and bites of unknown animal origin (n ϭ 10). Twelve ATCC strains were also tested. The numbers and species of isolates tested are given in Table 1 . Standard laboratory powders were supplied as follows: ofloxacin, levofloxacin, and DU-6859a, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan; sparfloxacin, Parke-Davis Pharmaceutical Research Division of Warner Lambert Co., Ann Arbor, Mich.; and ciprofloxacin, Bayer, West Haven, Conn.
Frozen cultures were transferred twice on Trypticase soy agar supplemented with 5% sheep blood or chocolate agar for the aerobes and brucella agar supplemented with hemin, vitamin K 1 , and 5% sheep blood for the anaerobes to ensure purity and good growth. Susceptibility testing was performed according to the methods of our prior reports (3, 4) and the National Committee for Clinical Laboratory Standards (11, 12) . Brucella agar supplemented with hemin, vitamin K 1 , and 5% laked sheep blood was the basal medium used for anaerobic species and for Eikenella corrodens, Weeksella zoohelcum, and Capnocytophaga species. Mueller-Hinton agar was used for staphylococci, and Mueller-Hinton agar supplemented with 5% sheep blood was used for the remainder of the organisms. Antimicrobial agents were reconstituted according to the manufacturers' instructions. Serial twofold dilutions of antimicrobial agents were prepared on the day of the test and added to the media in the following concentrations: DU-5869a, 0.001 to 4 g/ml for all isolates, and levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin, 0.001 to 4 g/ml for aerobes and 0.04 to 16 g/ml for anaerobes. The inoculum used for aerobes was 10 The results of our current study are summarized in Table 1 . DU-6859a was active against all aerobes at Յ0.125 g/ml and anaerobes at Յ0.5 g/ml, with the exception of Fusobacterium spp., which were all susceptible at Յ2 g/ml, and was the most active fluoroquinolone tested. In comparison, ciprofloxacin, ofloxacin, and levofloxacin possessed in vitro activities similar to those reported in our previous reports (3, 4) .
All the agents tested were active against all of the Pasteurella species tested, including Pasteurella multocida subsp. multocida, Pasteurella canis, Pasteurella multocida subsp. septica, Pasteurella multocida subsp. gallicida, Pasteurella dagmatis, and Pasteurella stomatis. Against the infrequently tested veterinary 
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and fastidious human isolates, such as Eikenella corrodens, Weeksella zoohelcum, Bacteroides tectum, Porphyromonas salivosa, and Prevotella heparinolytica, all five fluoroquinolones tested were quite active. Our study noted DU-6859a to be active against all isolates at Յ2 g/ml, which should be an achievable level in serum (9) . The other fluoroquinolones tested had several gaps in the coverage spectrum. Levofloxacin and sparfloxacin had improved activities against bite isolates compared to those of ciprofloxacin and ofloxacin but were still not active against many Fusobacterium nucleatum and other Fusobacterium strains. Our in vitro study supports further clinical evaluation of DU-6859a.
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